Fast Market Research recommends "Mexico Pharmaceuticals & Healthcare Report Q4 2012" from Business Monitor International, now available

Boston, MA -- (SBWire) -- 11/14/2012 --BMI View: Mexico has swapped positions with Brazil within BMI's Risk/Reward Rating assessment in Q412, indicating the possibility of fundamental changes in the two markets due to the macroeconomic factors. We note that the improving regulatory environment as well as the outperforming economic growth makes Mexican pharmaceutical market more attractive to multinational drugmakers.

Headline Expenditure Projections

- Pharmaceuticals: MXN161.45bn (US$12.99bn) in 2011 to MXN175.09bn (US$13.41bn) in 2012; +8.4% in local currency terms and +3.3% in US dollar terms. US growth forecasts lower from Q312 due to exchange rate factors.
- Healthcare: MXN872.57bn (US$70.21bn) in 2011 to MXN929.92bn (US$71.26bn) in 2012; +6.6% in local currency terms and +1.5 % in US dollar terms. US growth forecasts lower from Q312 due to exchange rate factors.
- Medical devices: MXN52.05bn (US$4.19bn) in 2011 to MXN57.61bn (US$4.42bn) in 2012; +10.7% in local currency terms and +5.4% in US dollar terms. US growth forecasts lower from Q312 due to exchange rate factors.

View Full Report Details and Table of Contents

Risk/Reward Rating: Mexico receives a Pharmaceutical and Healthcare Risk/Reward Rating (RRR) of 58.4 in Q412. Mexico swaps positions with Brazil ranking the fourth out of the 17 Americas markets surveyed in our proprietary regional RRR rating system. Globally, the country also moves upwards from 29th to 25th out of the 95 countries included in our pharmaceutical universe.

Key Trends And Developments

- BMI has revised up its forecast for Mexico's pharmaceutical market after analysis of recent positive developments and an improved macroeconomic outlook. This increasingly optimistic view is due to the government approving more innovative medicines from multinational drugmakers and facilitating patient access to the most commonly requested anti-cancer drugs. It has improved the sector's regulation system to require scientific proof of a treatment's effectiveness and evidence-based descriptions of drugs. There have also been more affordable medicines introduced in the generic drugs market by local and foreign companies. In addition, BMI has maintained its above-consensus real GDP growth forecast of 3.4% for 2012 and we have upgraded the 2013 forecast from 2.7% to 3.2%, despite Mexico's vulnerability to external shocks. The forecast is a result of our expectation of strong domestic demand and rising investment inflows, which will generally have a positive impact on the pharmaceutical and healthcare sectors.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Sweden Pharmaceuticals & Healthcare Report Q4 2012
- Cipher Pharmaceuticals Inc. (DND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Egypt Pharmaceuticals & Healthcare Report Q4 2012
- Turkey Pharmaceuticals & Healthcare Report Q4 2012
- Netherlands Pharmaceuticals & Healthcare Report Q4 2012
- Galectin Therapeutics, Inc. (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Latvia Pharmaceuticals & Healthcare Report Q4 2012
- Australia Pharmaceuticals & Healthcare Report Q4 2012
- Taiwan Pharmaceuticals & Healthcare Report Q4 2012
- Pharmaceutical & Healthcare Annual Deals Analysis 2012